SWOG clinical trial number
SWOG-9348

Evaluation of the Standard BCNU/DTIC/Cisplatin/Tamoxifen Regimen in Disseminated Malignant Melanoma, Phase II

Closed
Phase
Accrual
85%
Published
Abbreviated Title
Evaluation of the Standard BCNU/DTIC/Cisplatin/Tamoxifen Regimen in Disseminated Malignant Melanoma, Phase II
Activated
04/15/1994
Closed
04/15/1995

Research committees

Melanoma

Publication Information Expand/Collapse

2013

Future perspectives in melanoma research:Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"

PA Ascierto;AM Grimaldi;N Acquavella;L Borgognoni;L Calabro;N Cascinelli;A Cesano;M Del Vecchio;AM Eggermont;M Faries;S Ferrone;BA Fox;T Gajewski;J Galon;S Gnjatic;H Gogas;M Kashani-Sabet;HL Kaufman;J Larkin;RS Lo;A Mantovani;K Margolin;C Melief;G McArthur;G Palmieri;I Puzanov;A Ribas;B Seliger;J Sosman;P Suenaert;A Tarhini;G Trinchieri;F Vidal-Vanaclocha;E Wang;G Ciliberto;N Mozzillo;FM Marincola;M Thurin Journal of Translational Medicine 11:137

PMid: PMID23731854 | PMC number: PMC3681569

2008

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. [PMID18235113]

EL Korn;PY Liu;SJ Lee;JAW Chapman;D Niedzwiecki;VJ Suman;J Moon;VK Sondak;MB Atkins;EA Eisenhauer;W Parulekar;SN Markovic;S Saxman;JM Kirkwood Journal of Clinical Oncology 26(4):527-534

1998

Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: A Southwest Oncology Group study.

KA Margolin;PY Liu;LE Flaherty;JA Sosman;MJ Walker;JW Smith II;WS Fletcher;GR Weiss;JM Unger;VK Sondak Journal of Clinical Oncology 16(2):664-669

1997

Low antitumor activity of BCNU, DTIC, cisplatin (DDP) and tamoxifen (TAM) in advanced melanoma: a Southwest Oncology Group study.

K Margolin;PY Liu;L Flaherty;J Sosman;J Unger;V Sondak Proc of the American Society of Clinical Oncology 16:495a(#1783)

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/EA6174

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Research Committee(s)
Melanoma
Activated
10/01/2018
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6141

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Research Committee(s)
Melanoma
Activated
09/10/2015
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6134

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
Research Committee(s)
Melanoma
Activated
07/13/2015
Open
Phase